Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Grip, Olof ^a   Janciauskiene, Sabrina ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; BUDESONIDE; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CXCR3; CYTOKINE; EOTAXIN; EOTAXIN 3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESALAZINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 4; PADGEM PROTEIN; PREDNISOLONE; THROMBOMODULIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; CXCL10 PROTEIN, HUMAN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HUMAN; IRRITABLE COLON; MALE; MUCOSA INFLAMMATION; PROTEIN BLOOD LEVEL; T LYMPHOCYTE ACTIVATION; BLOOD; METABOLISM;

ADULT; C-REACTIVE PROTEIN; CHEMOKINE CXCL10; CROHN DISEASE; CYTOKINES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRROLES; YOUNG ADULT;

EID: 65549131046     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005263     Document Type: Article

References (52)

1. Allen SJ, Crown SE, Handel TM (2007) Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 25: 787-820.
2. Sallusto F, Mackay CR, Lanzavecchia A (2000) The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 18: 593-620.
3. Moser B, Willimann K (2004) Chemokines: role in inflammation and immune surveillance. Ann Rheum Dis 63 Suppl 2: ii84-ii89.
4. Luster AD (2002) The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 14: 129-135.
5. D'Ambrosio D, Iellem A, Bonecchi R, Mazzeo D, Sozzani S, et al. (1998) Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol 161: 5111-5115.
6. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A (1998) Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 187: 875-883.
7. Baggiolini M (1998) Chemokines and leukocyte traffic. Nature 392: 565-568.
8. Barnes PJ (1997) Nuclear factor-kappa B. Int J Biochem Cell Biol 29: 867-870.
9. Mantovani A (1999) The chemokine system: redundancy for robust outputs. Immunol Today 20: 254-257.
10. Heystek HC, Thierry AC, Soulard P, Moulon C (2003) Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int Immunol 15: 827-835.
11. Jain MK, Ridker PM (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4: 977-987.
12. Waehre T, Damas JK, Gullestad L, Holm AM, Pedersen TR, et al. (2003) Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 41: 1460-1467.
13. Albert MA, Danielson E, Rifai N, Ridker PM (2001) Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. Jama 286: 64-70.
14. Grip O, Janciauskiene S, Lindgren S (2004) Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin. Inflamm Bowel Dis 10: 193-200.
15. Grip O, Janciauskiene S, Bredberg A (2008) Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease. Br J Pharmacol 155: 1085-1092.
16. Chen W, Paulus B, Shu D, Wilson, Chadwick V (2001) Increased serum levels of eotaxin in patients with inflammatory bowel disease. Scand J Gastroenterol 36: 515-520.
17. Jugde F, Alizadeh M, Boissier C, Chantry D, Siproudhis L, et al. (2001) Quantitation of chemokines (MDC, TARC) expression in mucosa from Crohn's disease and ulcerative colitis. Eur Cytokine Netw 12: 468-477.
18. Uguccioni M, Gionchetti P, Robbiani DF, Rizzello F, Peruzzo S, et al. (1999) Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol 155: 331-336.
19. Baumgart DC, Carding SR (2007) Inflammatory bowel disease: cause and immunobiology. Lancet 369: 1627-1640.
20. Zhong W, Kolls JK, Chen H, McAllister F, Oliver PD, et al. (2008) Chemokines orchestrate leukocyte trafficking in inflammatory bowel disease. Front Biosci 13: 1654-1664.
21. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, et al. (1998) The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101: 746-754.
22. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, et al. (1996) Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184: 963-969.
23. Gasperini S, Marchi M, Calzetti F, Laudanna C, Vicentini L, et al. (1999) Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol 162: 4928-4937.
24. Garcia-Lopez MA, Sanchez-Madrid F, Rodriguez-Frade JM, Mellado M, Acevedo A, et al. (2001) CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells. Lab Invest 81: 409-418.
25. Iqbal N, Oliver JR, Wagner FH, Lazenby AS, Elson CO, et al. (2002) T helper 1 and T helper 2 cells are pathogenic in an antigen-specific model of colitis. J Exp Med 195: 71-84.
26. Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, Marth T, et al. (2005) Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 11: 16-23.
27. Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, Chinen H, et al. (2008) IL-23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut.
28. Luster AD, Ravetch JV (1987) Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 166: 1084-1097.
29. Banks C, Bateman A, Payne R, Johnson P, Sheron N (2003) Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 199: 28-35.
30. Dwinell MB, Lugering N, Eckmann L, Kagnoff MF (2001) Regulated production of interferon-inducible T-cell chemoattractants by human intestinal epithelial cells. Gastroenterology 120: 49-59.
31. Singh UP, Venkataraman C, Singh R, Lillard JW Jr (2007) CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication. Endocr Metab Immune Disord Drug Targets 7: 111-123.
32. Singh UP, Singh S, Taub DD, Lillard JW Jr (2003) Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10-/- mice. J Immunol 171: 1401-1406.
33. Hyun JG, Lee G, Brown JB, Grimm GR, Tang Y, et al. (2005) Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice. Inflamm Bowel Dis 11: 799-805.
34. Blanco-Colio LM, Martin-Ventura JL, de Teresa E, Farsang C, Gaw A, et al. (2007) Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J 153: 881-888.
35. Bolewski A, Lipiecki J, Plewa R, Burchardt P, Siminiak T (2008) The effect of atorvastatin treatment on lipid profile and adhesion molecule levels in hypercholesterolemic patients: relation to low-density lipoprotein receptor gene polymorphism. Cardiology 111: 140-146.
36. Kushiya F, Wada H, Ooi K, Sakurai Y, Sakaguchi A, et al. (2005) Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis. Am J Hematol 78: 1-6.
37. Rauch U, Osende JI, Chesebro JH, Fuster V, Vorchheimer DA, et al. (2000) Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis 153: 181-189.
38. Rosenson RS, Tangney CC, Casey LC (1999) Inhibition of proinflammatory cytokine production by pravastatin. Lancet 353: 983-984.
39. Takahashi HK, Mori S, Iwagaki H, Yoshino T, Tanaka N, et al. (2005) Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes. J Leukoc Biol 77: 400-407.
40. Wagner AH, Schwabe O, Hecker M (2002) Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol 136: 143-149.
41. Sanders DS (2005) Mucosal integrity and barrier function in the pathogenesis of early lesions in Crohn's disease. J Clin Pathol 58: 568-572.
42. Scaldaferri F, Sans M, Vetrano S, Graziani C, De Cristofaro R, et al. (2007) Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J Clin Invest 117: 1951-1960.
43. Andoh A, Tsujikawa T, Hata K, Araki Y, Kitoh K, et al. (2005) Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am J Gastroenterol 100: 2042-2048.
44. Goke M, Hoffmann JC, Evers J, Kruger H, Manns MP (1997) Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease. J Gastroenterol 32: 480-486.
45. Ortego M, Bustos C, Hernandez-Presa MA, Tunon J, Diaz C, et al. (1999) Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 147: 253-261.
46. Liao JK (2002) Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110: 285-288.
47. Zhang FL, Casey PJ (1996) Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65: 241-269.
48. Wong CK, Li PW, Lam CW (2007) Intracellular JNK, p38 MAPK and NF-kappaB regulate IL-25 induced release of cytokines and chemokines from costimulated T helper lymphocytes. Immunol Lett 112: 82-91.
49. Cammarano MS, Minden A (2001) Dbl and the Rho GTPases activate NF kappa B by I kappa B kinase (IKK)-dependent and IKK-independent pathways. J Biol Chem 276: 25876-25882.
50. Marinissen MJ, Chiariello M, Gutkind JS (2001) Regulation of gene expression by the small GTPase Rho through the ERK6 (p38 gamma) MAP kinase pathway. Genes Dev 15: 535-553.
51. Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, et al. (2004) The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. Mol Cell 14: 29-41.
52. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, et al. (2005) Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 11: 707-712.